390 related articles for article (PubMed ID: 32836055)
1. BRAF mutations in KIT/PDGFRA positive gastrointestinal stromal tumours (GISTs): Is their frequency underestimated?
Jašek K; Váňová B; Grendár M; Štanclová A; Szépe P; Hornáková A; Holubeková V; Plank L; Lasabová Z
Pathol Res Pract; 2020 Nov; 216(11):153171. PubMed ID: 32836055
[TBL] [Abstract][Full Text] [Related]
2. Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors.
Jasek K; Buzalkova V; Minarik G; Stanclova A; Szepe P; Plank L; Lasabova Z
Virchows Arch; 2017 Jan; 470(1):29-36. PubMed ID: 27864688
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal stromal tumors - Summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects.
Kalfusova A; Linke Z; Kalinova M; Krskova L; Hilska I; Szabova J; Vicha A; Kodet R
Pathol Res Pract; 2019 Dec; 215(12):152708. PubMed ID: 31708372
[TBL] [Abstract][Full Text] [Related]
4. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
[TBL] [Abstract][Full Text] [Related]
6. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors.
Rossi S; Sbaraglia M; Dell'Orto MC; Gasparotto D; Cacciatore M; Boscato E; Carraro V; Toffolatti L; Gallina G; Niero M; Pilozzi E; Mandolesi A; Sessa F; Sonzogni A; Mancini C; Mazzoleni G; Romeo S; Maestro R; Dei Tos AP
Oncotarget; 2016 May; 7(21):30109-18. PubMed ID: 27097112
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of an Italian series of sporadic GISTs.
Origone P; Gargiulo S; Mastracci L; Ballestrero A; Battistuzzi L; Casella C; Comandini D; Cusano R; Dei Tos AP; Fiocca R; Garuti A; Ghiorzo P; Martinuzzi C; Toffolatti L; ; Bianchi Scarrà G
Gastric Cancer; 2013 Oct; 16(4):596-601. PubMed ID: 23291969
[TBL] [Abstract][Full Text] [Related]
8. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.
Agaram NP; Wong GC; Guo T; Maki RG; Singer S; Dematteo RP; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2008 Oct; 47(10):853-9. PubMed ID: 18615679
[TBL] [Abstract][Full Text] [Related]
9. Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors.
Celestino R; Lima J; Faustino A; Vinagre J; Máximo V; Gouveia A; Soares P; Lopes JM
Eur J Hum Genet; 2013 May; 21(5):503-10. PubMed ID: 22948025
[TBL] [Abstract][Full Text] [Related]
10. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
Martinho O; Gouveia A; Viana-Pereira M; Silva P; Pimenta A; Reis RM; Lopes JM
Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767
[TBL] [Abstract][Full Text] [Related]
11. Oncogene mutational analysis in imatinib naive population of gastrointestinal stromal tumor patients.
Ali Abuderman AW; M Aldakheel F
Cell Mol Biol (Noisy-le-grand); 2020 Dec; 66(8):26-32. PubMed ID: 34174973
[TBL] [Abstract][Full Text] [Related]
12. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
Rossi S; Gasparotto D; Miceli R; Toffolatti L; Gallina G; Scaramel E; Marzotto A; Boscato E; Messerini L; Bearzi I; Mazzoleni G; Capella C; Arrigoni G; Sonzogni A; Sidoni A; Mariani L; Amore P; Gronchi A; Casali PG; Maestro R; Dei Tos AP
Am J Surg Pathol; 2015 Jul; 39(7):922-30. PubMed ID: 25970686
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.
Gao J; Li J; Li Y; Li Z; Gong J; Wu J; Liu N; Dong B; Qi C; Li J; Shen L
Oncotarget; 2016 May; 7(21):30241-9. PubMed ID: 26848617
[TBL] [Abstract][Full Text] [Related]
14. Multiple sporadic gastrointestinal stromal tumours arising at different gastrointestinal sites: pattern of involvement of the muscularis propria as a clue to independent primary GISTs.
Agaimy A; Märkl B; Arnholdt H; Wünsch PH; Terracciano LM; Dirnhofer S; Hartmann A; Tornillo L; Bihl MP
Virchows Arch; 2009 Aug; 455(2):101-8. PubMed ID: 19572146
[TBL] [Abstract][Full Text] [Related]
15. Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.
Bombac A; Zakotnik B; Bucic M; Setrajcic Dragos V; Gazic B; Stegel V; Klancar G; Novakovic S
Int J Oncol; 2020 Jun; 56(6):1468-1478. PubMed ID: 32236636
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST).
Daniels M; Lurkin I; Pauli R; Erbstösser E; Hildebrandt U; Hellwig K; Zschille U; Lüders P; Krüger G; Knolle J; Stengel B; Prall F; Hertel K; Lobeck H; Popp B; Theissig F; Wünsch P; Zwarthoff E; Agaimy A; Schneider-Stock R
Cancer Lett; 2011 Dec; 312(1):43-54. PubMed ID: 21906875
[TBL] [Abstract][Full Text] [Related]
17. A smooth muscle-derived, Braf-driven mouse model of gastrointestinal stromal tumor (GIST): evidence for an alternative GIST cell-of-origin.
Kondo J; Huh WJ; Franklin JL; Heinrich MC; Rubin BP; Coffey RJ
J Pathol; 2020 Dec; 252(4):441-450. PubMed ID: 32944951
[TBL] [Abstract][Full Text] [Related]
18. Gastric GISTs: Analysis of c-Kit, PDGFRA and BRAF mutations in relation to prognosis and clinical pathological characteristics of patients - A GIRCG study.
Capelli L; Petracci E; Quagliuolo V; Saragoni L; Colombo P; Morgagni P; Calistri D; Tomezzoli A; Di Cosmo M; Roviello F; Vindigni C; Coniglio A; Villanacci V; Catarci M; Coppola L; Alfieri S; Ricci R; Capella C; Rausei S; Gulino D; Amadori D; Ulivi P;
Eur J Surg Oncol; 2016 Aug; 42(8):1206-14. PubMed ID: 27265040
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
[TBL] [Abstract][Full Text] [Related]
20. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
Lasota J; Miettinen M
Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
